

PHARMACY POLICY STATEMENT

POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (pJIA)

For initial authorization:

1. Member must be 2 years of age or older; AND
2. Member has a confirmed diagnosis of active pJIA; AND
3. Must have a documented negative TB test (i.e., tuberculosis skin test (PPD), interferon-gamma release assay (IGRA)) within 12 months prior to starting therapy; AND
4. Medication must be prescribed by or in consultation with a rheumatologist; AND



For reauthorization :

11/01/2020	Updated list of preferred agents and drug trials for all diagnoses to match Ohio Department of Medicaid Unified Preferred Drug List. Added that if member previously tried a non-preferred option in the same drug class as preferred options, the trial is accepted.
11/12/2020	<p>New diagnosis of pJIA added. Replaced list of excluded diagnoses with the generic statement. Updated references. For all diagnoses: Removed repeat TB in reauth for all diagnoses.</p> <p>For <u>AS</u>: Removed list of symptoms of spondyloarthritis because imaging result should be sufficient. Removed peripheral arthritis requirement – not relevant for this diagnosis.</p> <p>For <u>PsA</u>: Age requirement expanded to 2 years or older. Updated dosing and biologic trials reflective of age label change. Added requirement of diagnosis of PsA. Changed the trial section to be 4 weeks of an NSAID AND 3 months of a DMARD unless other circumstances apply (e.g., concomitant axial disease, severe PsA, etc.).</p> <p>For <u>RA</u>: Changed the trials to require methotrexate as one of the non-biologic DMARD trials; only one trial is needed if member has poor prognostic factors.</p>

References:

3.6 (h)10.5 (s)-22.6 (t)4.2.44 1.44 re ff 12o7 (55t)4.2.4r2o7 (52o



Effective date: 04/01/2021

Revised date: 11/12/2020